Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
MYR Group to acquire Valley Electric and Comet Electric for $328M
10:49am, Thursday, 28'th May 2026
MYR Group Inc. (NASDAQ:MYRG) has agreed to acquire all outstanding capital stock of Valley Holdings Inc and its subsidiaries, including Valley Electric...
AtaiBeckley launches mental health patient impact grant program
09:58am, Thursday, 28'th May 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the launch of a new Patient Impact Grant Program aimed at supporting non-profit organizations working to improve mental health outcomes through
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
09:00am, Thursday, 28'th May 2026
Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK, May
Dow slips as soft GDP data offsets cooler inflation reading
07:56am, Thursday, 28'th May 2026
11:55am: Balancing act Gina Bolvin, President of Bolvin Wealth Management Group, said today’s economic data underscores a “tougher balancing act” for...
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
06:00am, Wednesday, 27'th May 2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by de
FTSE 100 Live: Index little moved as Aviva, Burberry, 3i and ex-div heavyweights drag
04:25am, Thursday, 14'th May 2026
8.24am: HSBC, BP among morning's ex-div stocks The FTSE 100 is also facing a near 20-point drag from stocks trading ex-dividend this morning, led by HSBC,...
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
01:07pm, Wednesday, 13'th May 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple Phase III and Phase II readouts expected ov
Tesla capex outlook climbs as company deepens AI investments, UBS says
11:51am, Wednesday, 13'th May 2026
Tesla Inc (NASDAQ:TSLA) had its price target raised modestly by UBS to $364 from $352, as the bank said the electric vehicle maker’s first-quarter update...
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
09:06am, Wednesday, 13'th May 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple...
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances
09:25am, Tuesday, 12'th May 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treatment-resistant depression therapy in the second quarter of 2026, while projecting its cas
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
08:00am, Tuesday, 12'th May 2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
11:53am, Saturday, 09'th May 2026
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Microsoft Q3 preview: Jefferies says it's time to reset the narrative
11:55am, Monday, 27'th Apr 2026
Microsoft Corp (NASDAQ:MSFT) shares have slid roughly 12% since its fiscal second-quarter results, and heading into Wednesday's fiscal third-quarter report,...
These 3 Psychedelic Stocks Activated After Trump's Executive Order
11:15am, Monday, 27'th Apr 2026
The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile dom
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
08:36am, Monday, 27'th Apr 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participan
